Evidence map›Paper›PMID 36771126›Full record

ArticleMolecules (Basel, Switzerland)2023

Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice.

Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Oliver C McGeheeSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Hassan Y EbrahimSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0001-9057-4582
Ashkan H RadSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0002-5748-4160
Khaldoun S AbdelwahedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Ethar A MudhishSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0003-3677-6575
Judy A KingDepartment of Integrated Medical Education, Thomas F. Frist, Jr. College of Medicine, Belmont University, 1900 Belmont Boulevard, Nashville, TN 37212, USA.
Iman E HelalSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0001-9410-0210
Sharon A MeyerSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Khalid A El SayedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0002-1456-4064
University of Louisiana at Monroe · USBelmont University · US

Funding

Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppressionR21CA263290 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI EL SAYED, KHALID A · 2022 to 2023
$344k
Edward Via College of Osteopathic Medicine VCOM1038513ULMNCI NIH HHS R21 CA263290NCI NIH HHS R21CA263290
6 · The paper itself

Abstract

The proprotein convertase subtilisin kexin type 9 (PCSK9) emerged as a molecular target of great interest for the management of cardiovascular disorders due to its ability to reduce low density lipoprotein (LDL) cholesterol by binding and targeting at LDLR for lysosomal degradation in cells. Preliminary studies revealed that pseurotin A (PsA), a spiro-heterocyclic γ-lactam alkaloid from several marine and terrestrial

Indexed as

Arthritis, PsoriaticProstatic NeoplasmsAnimalsHumansMaleMiceProprotein Convertase 9Proprotein ConvertasesProstatePyrrolidinonesReceptors, LDLSerine EndopeptidasesPCSK9 protein, humanPcsk9 protein, mouseProprotein Convertase 9Proprotein ConvertasespseurotinPyrrolidinonesReceptors, LDLSerine Endopeptidasesacute oral toxicityproprotein convertase subtilisin/kexin type 9 (PCSK9)pseurotin A

Identifiers

PMID36771126
PMCPMC9922019
OpenAlexW4319791786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.